Scholars@Duke

Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.

Publication ,  Conference
Shi, Q; Sobrero, AF; Shields, AF; Yoshino, T; Paul, J; Taieb, J; Sougklakos, I; Kerr, R; Labianca, R; Meyerhardt, JA; Bonnetain, F; Renfro, LA ...
Published in: Journal of Clinical Oncology
May 20, 2017
Published version (DOI) Publisher Link

LBA1 The full, final text of this abstract will be available at abstracts.asco.org at 7:30 AM (EDT) on Sunday, June 4, 2017, and in the Annual Meeting Proceedings online supplement to the June 20, 2017, issue of the Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.

Duke Scholars

Donna Niedzwiecki
Author Donna Niedzwiecki Biostatistics & Bioinformatics, Division of Biostatistics

Published In

Journal of Clinical Oncology

DOI

10.1200/jco.2017.35.15_suppl.lba1

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2017

Volume

35

Issue

15_suppl

Start / End Page

LBA1 / LBA1

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Shi, Q., Sobrero, A. F., Shields, A. F., Yoshino, T., Paul, J., Taieb, J., … Iveson, T. (2017). Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. In Journal of Clinical Oncology (Vol. 35, pp. LBA1–LBA1). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2017.35.15_suppl.lba1
Shi, Qian, Alberto F. Sobrero, Anthony Frank Shields, Takayuki Yoshino, James Paul, Julien Taieb, Ioannis Sougklakos, et al. “Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.” In Journal of Clinical Oncology, 35:LBA1–LBA1. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.lba1.
Shi, Qian, et al. “Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.” Journal of Clinical Oncology, vol. 35, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2017, pp. LBA1–LBA1. Crossref, doi:10.1200/jco.2017.35.15_suppl.lba1.
Shi Q, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Sougklakos I, Kerr R, Labianca R, Meyerhardt JA, Bonnetain F, Watanabe T, Boukovinas I, Renfro LA, Grothey A, Niedzwiecki D, Torri V, Andre T, Sargent DJ, Iveson T. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017. p. LBA1–LBA1.

Published In

Journal of Clinical Oncology

DOI

10.1200/jco.2017.35.15_suppl.lba1

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2017

Volume

35

Issue

15_suppl

Start / End Page

LBA1 / LBA1

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences